There’s two ways of looking at this …
They wanted to give an opportunity for long term shareholders to participate at a low cost as this will be the last chance before the interim results are known.
If successful …
At that point it will no longer be shareholders funding any further .
It’s good to know …. In March 2024, the Company updated the market to report that 11 patients had
been dosed in the Phase 2a trial at that time
.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
